NPPA has fixed ceiling prices of 355 medicines, 882 formulations: Minister tells Parliament

Published On 2021-07-28 10:11 GMT   |   Update On 2023-10-16 09:24 GMT

New Delhi: The National Pharmaceutical Pricing Authority has fixed the ceiling prices of 355 medicines and 882 formulations for medicines under National List of Essential Medicines, 2015 (Schedule-I of DPCO, 2013), the Parliament was informed on Tuesday.This came during a recent Lok Sabha session, wherein, Minister of Chemicals and Fertilisers Mansukh Mandaviya said in a written reply to a...

Login or Register to read the full article

New Delhi: The National Pharmaceutical Pricing Authority has fixed the ceiling prices of 355 medicines and 882 formulations for medicines under National List of Essential Medicines, 2015 (Schedule-I of DPCO, 2013), the Parliament was informed on Tuesday.

This came during a recent Lok Sabha session, wherein, Minister of Chemicals and Fertilisers Mansukh Mandaviya said in a written reply to a query, " Most of the drugs that are part of COVID management protocol have ceiling prices, viz., Paracetamol, Dexamethasone, Methyl Prednisolone, IVIGs, Enoxaparin, Budesonide, Heparin and Amphotericin etc."

The National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals, as an on-going process, with the help of Price Monitoring and Resource Units (PMRUs) and State Drug Controllers (SDCs) undertake activities related to market-based data collection, monitoring of the notified prices of medicines and detection of violation of the provisions of Drug (Price Control) Order, 2013 (DPCO, 2013).

NPPA fixes the ceiling prices of scheduled formulations as per provisions of DPCO, 2013 and monitors the prices of non-scheduled drugs so as to ensure that their prices do not increase beyond 10 percent in a year, he added.

Also Read: NPPA fixes price of 14 formulations including Diabetes drugs and antibiotics, Details

In the case of few non-scheduled medicines like Remdesivir, which are part of COVID protocol and are non-scheduled, on Government intervention, MRPs of various brands of Remdesivir have been reduced voluntarily by the major manufacturers/marketers of the Remdesivir Injection (lyophilized). Inter-brand MRPs that varied up to Rs 5400/ per vial were brought down to less than Rs 3500/-.

"Furthermore, to facilitate availability and ensure affordability, NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level vide notification dated 3rd June, 2021 and on Pulse Oximeter, Glucometer, BP Monitor, Nebulizer and Digital Thermometer vide notification dated 13th July, 2021," the Minister said.

In addition, Retail prices for 1,640 formulations have been fixed under DPCO, 2013 till date and in recent years exercising extraordinary powers under DPCO, 2013 in public interest, NPPA has fixed the prices of following drugs and medical devices:

(i) Ceiling price of Stents in February, 2017

(ii) Ceiling price of Knee Implants in August, 2017

(iii) Capped trade margin on selected 42 anti-cancer drugs in February, 2019.

Also Read: NPPA caps trade margin for 5 medical devices used in COVID management at 70 percent

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News